[{"id":"0e3b7313-f974-4ff1-8e45-f190a050cd4d","acronym":"","url":"https://clinicaltrials.gov/study/NCT06959693","created_at":"2025-09-07T01:30:19.058Z","updated_at":"2025-09-07T01:30:19.058Z","phase":"Phase 2/3","brief_title":"A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)","source_id_and_acronym":"NCT06959693","lead_sponsor":"Sun Yat-sen University","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • Enweida (envafolimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 590","initiation":"Initiation: 06/01/2025","start_date":" 06/01/2025","primary_txt":" Primary completion: 09/30/2028","primary_completion_date":" 09/30/2028","study_txt":" Completion: 06/30/2030","study_completion_date":" 06/30/2030","last_update_posted":"2025-05-06"},{"id":"676a91c9-2aba-4008-872e-5a9b996188c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06791083","created_at":"2025-02-25T18:40:00.939Z","updated_at":"2025-02-25T18:40:00.939Z","phase":"Phase 2","brief_title":"Clinical Study of Envafolimab Combined With Fruquintinib and Chemotherapy for Neoadjuvant Treatment of Gastric Cancer","source_id_and_acronym":"NCT06791083","lead_sponsor":"First Affiliated Hospital of Fujian Medical University","biomarkers":" CD8 • CD31 • PECAM1","pipe":"","alterations":" ","tags":["CD8 • CD31 • PECAM1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fruzaqla (fruquintinib) • Enweida (envafolimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/20/2024","start_date":" 06/20/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-01-24"},{"id":"1cc3eb18-79f5-432b-996d-68c0fa40cdd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT06772233","created_at":"2025-02-26T06:55:02.549Z","updated_at":"2025-02-26T06:55:02.549Z","phase":"Phase 2","brief_title":"A Study of Regorafenib Combined with Envafolimab for Metastatic Gastrointestinal Stromal Tumors with Kit Gene Exon 17 Mutation That Failed Standard Treatment","source_id_and_acronym":"NCT06772233","lead_sponsor":"Peking University","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sunitinib • Stivarga (regorafenib) • Enweida (envafolimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 01/01/2025","start_date":" 01/01/2025","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2025-01-13"},{"id":"83f56344-90cd-467e-b21a-af268ac41927","acronym":"neovision","url":"https://clinicaltrials.gov/study/NCT06734182","created_at":"2025-02-25T19:17:44.245Z","updated_at":"2025-02-25T19:17:44.245Z","phase":"Phase 2","brief_title":"Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer","source_id_and_acronym":"NCT06734182 - neovision","lead_sponsor":"Guangdong Provincial People's Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" PD-L1 expression • HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Aidixi (disitamab vedotin) • Enweida (envafolimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 06/22/2024","start_date":" 06/22/2024","primary_txt":" Primary completion: 06/22/2027","primary_completion_date":" 06/22/2027","study_txt":" Completion: 06/22/2028","study_completion_date":" 06/22/2028","last_update_posted":"2024-12-16"},{"id":"8fc7055a-dde1-4071-9f3b-d016eed452de","acronym":"","url":"https://clinicaltrials.gov/study/NCT04891198","created_at":"2021-05-18T12:02:07.091Z","updated_at":"2024-07-02T16:35:11.517Z","phase":"Phase 2","brief_title":"ENVAFOLIMAB Single-agent Treatment in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04891198","lead_sponsor":"3D Medicines (Sichuan) Co., Ltd.","biomarkers":" TMB","pipe":" | ","alterations":" TMB-H","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enweida (envafolimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 08/06/2021","start_date":" 08/06/2021","primary_txt":" Primary completion: 08/30/2027","primary_completion_date":" 08/30/2027","study_txt":" Completion: 04/30/2028","study_completion_date":" 04/30/2028","last_update_posted":"2024-04-03"},{"id":"7e48b936-3805-41f8-8a0b-097880eb98b4","acronym":"CEIL","url":"https://clinicaltrials.gov/study/NCT05959356","created_at":"2023-07-27T18:08:40.272Z","updated_at":"2024-07-02T16:35:13.375Z","phase":"Phase 2","brief_title":"Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05959356 - CEIL","lead_sponsor":"Sun Yat-sen University","biomarkers":" EGFR • HER-2 • KRAS • BRAF • NRAS • SMAD4","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • NRAS mutation • BRAF wild-type • SMAD4 mutation","tags":["EGFR • HER-2 • KRAS • BRAF • NRAS • SMAD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • NRAS mutation • BRAF wild-type • SMAD4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • Enweida (envafolimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 198","initiation":"Initiation: 11/09/2023","start_date":" 11/09/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2024-03-21"},{"id":"a08d6ccc-81d6-47d8-b4ca-c0610cdd67c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06321081","created_at":"2024-03-21T20:40:12.444Z","updated_at":"2024-07-02T16:35:13.604Z","phase":"Phase 2","brief_title":"ICE Study: Combination of Irinotecan Plus Cetuximab and Envafolimab as a Rechallenge Regimen in mCRC","source_id_and_acronym":"NCT06321081","lead_sponsor":"Beijing Hospital","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • irinotecan • Enweida (envafolimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 03/01/2024","start_date":" 03/01/2024","primary_txt":" Primary completion: 02/14/2026","primary_completion_date":" 02/14/2026","study_txt":" Completion: 08/14/2026","study_completion_date":" 08/14/2026","last_update_posted":"2024-03-20"},{"id":"82bacc72-96c6-424d-8fe5-1ba4488048d9","acronym":"KN035-CN-017","url":"https://clinicaltrials.gov/study/NCT06123754","created_at":"2023-11-09T16:12:38.842Z","updated_at":"2024-07-02T16:35:21.602Z","phase":"Phase 3","brief_title":"Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC","source_id_and_acronym":"NCT06123754 - KN035-CN-017","lead_sponsor":"3D Medicines (Sichuan) Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enweida (envafolimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 390","initiation":"Initiation: 11/17/2023","start_date":" 11/17/2023","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2024-01-31"},{"id":"9c5ff37e-9dc9-4ed2-bf5e-422fc0b946b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT03667170","created_at":"2021-01-17T17:33:19.222Z","updated_at":"2024-07-02T16:35:21.422Z","phase":"Phase 2","brief_title":"KN035 for dMMR/MSI-H Advanced Solid Tumors","source_id_and_acronym":"NCT03667170","lead_sponsor":"3D Medicines (Sichuan) Co., Ltd.","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enweida (envafolimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 08/22/2018","start_date":" 08/22/2018","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/15/2025","study_completion_date":" 12/15/2025","last_update_posted":"2024-01-31"},{"id":"4953d931-42c7-4262-bf45-09373d17a177","acronym":"","url":"https://clinicaltrials.gov/study/NCT05237349","created_at":"2022-02-14T16:52:49.950Z","updated_at":"2024-07-02T16:35:24.575Z","phase":"Phase 2","brief_title":"Envafolimab Combined With Chemotherapy in Metastatic or Recurrent Gastric Adenocarcinoma","source_id_and_acronym":"NCT05237349","lead_sponsor":"Liangjun Zhu M.M.","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" PD-L1 expression • HER-2 expression","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e oxaliplatin • Enweida (envafolimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-01-04"},{"id":"8192c559-1830-4f39-b13f-bb42dc9d1236","acronym":"","url":"https://clinicaltrials.gov/study/NCT06059261","created_at":"2023-09-28T14:10:34.158Z","updated_at":"2024-07-02T16:35:35.305Z","phase":"Phase 2","brief_title":"Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.","source_id_and_acronym":"NCT06059261","lead_sponsor":"Chongqing University Cancer Hospital","biomarkers":" PD-L1","pipe":" | ","alterations":" MSI-H/dMMR","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Enweida (envafolimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/01/2023","start_date":" 10/01/2023","primary_txt":" Primary completion: 10/01/2027","primary_completion_date":" 10/01/2027","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2023-09-28"},{"id":"c0a4e57f-0918-48f8-810e-20dfa5fe1d46","acronym":"","url":"https://clinicaltrials.gov/study/NCT06041724","created_at":"2023-09-18T15:13:24.814Z","updated_at":"2024-07-02T16:35:36.736Z","phase":"Phase 2","brief_title":"Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy Treat of Advanced Mucosal Melanoma","source_id_and_acronym":"NCT06041724","lead_sponsor":"Fudan University","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression • BRAF V600","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • temozolomide • Enweida (envafolimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 46","initiation":"Initiation: 09/18/2023","start_date":" 09/18/2023","primary_txt":" Primary completion: 09/18/2025","primary_completion_date":" 09/18/2025","study_txt":" Completion: 03/18/2026","study_completion_date":" 03/18/2026","last_update_posted":"2023-09-18"},{"id":"2b9bda8e-33da-493d-b8b0-3cfd0cf594f6","acronym":"","url":"https://clinicaltrials.gov/study/NCT06030934","created_at":"2023-09-11T16:10:25.772Z","updated_at":"2024-07-02T16:35:37.514Z","phase":"Phase 2","brief_title":"Study of The Second-line Treatment of Advanced Gastric / Gastroesophageal Junction Adenocarcinoma With Envafolimab and Lenvatinib Combined With Paclitaxel-albumin","source_id_and_acronym":"NCT06030934","lead_sponsor":"Fudan University","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • Lenvima (lenvatinib) • Enweida (envafolimab)"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 30","initiation":"Initiation: 10/24/2022","start_date":" 10/24/2022","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2023-09-11"},{"id":"e7a1a25a-cab4-4cbd-b715-15474146b001","acronym":"ICONIC","url":"https://clinicaltrials.gov/study/NCT05914389","created_at":"2023-06-22T19:11:48.865Z","updated_at":"2024-07-02T16:35:40.681Z","phase":"Phase 2","brief_title":"Induction Chemotherapy Combined With Neoadjuvant Immunotherapy for MSS Colon Cancer","source_id_and_acronym":"NCT05914389 - ICONIC","lead_sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","biomarkers":" FLT3LG","pipe":"","alterations":" ","tags":["FLT3LG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e capecitabine • oxaliplatin • Enweida (envafolimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 08/01/2023","start_date":" 08/01/2023","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 08/01/2030","study_completion_date":" 08/01/2030","last_update_posted":"2023-08-08"},{"id":"87def125-04a6-4b33-bb5e-5e9e6e36a732","acronym":"Endouble","url":"https://clinicaltrials.gov/study/NCT05203276","created_at":"2022-01-24T17:01:44.348Z","updated_at":"2024-07-02T16:35:45.136Z","phase":"Phase 2","brief_title":"Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC","source_id_and_acronym":"NCT05203276 - Endouble","lead_sponsor":"The First People's Hospital of Lianyungang","biomarkers":" EGFR • PD-L1 • ALK • ROS1","pipe":"","alterations":" ","tags":["EGFR • PD-L1 • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enweida (envafolimab) • Endostar (recombinant human endostatin)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 05/30/2024","primary_completion_date":" 05/30/2024","study_txt":" Completion: 06/30/2024","study_completion_date":" 06/30/2024","last_update_posted":"2023-06-22"},{"id":"5b93c4c2-b585-41d4-925d-4127b0bc2a31","acronym":"ST-CR01","url":"https://clinicaltrials.gov/study/NCT05755009","created_at":"2023-03-06T15:01:36.116Z","updated_at":"2024-07-02T16:35:53.932Z","phase":"Phase 2","brief_title":"High- and Low-dose Radiotherapy Combined With Envafolimab for Metastatic Solid Tumor","source_id_and_acronym":"NCT05755009 - ST-CR01","lead_sponsor":"Jiangxi Provincial Cancer Hospital","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enweida (envafolimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 33","initiation":"Initiation: 03/01/2023","start_date":" 03/01/2023","primary_txt":" Primary completion: 02/20/2024","primary_completion_date":" 02/20/2024","study_txt":" Completion: 02/20/2025","study_completion_date":" 02/20/2025","last_update_posted":"2023-03-07"},{"id":"c7668b88-2651-4a31-93c7-e5613e157905","acronym":"","url":"https://clinicaltrials.gov/study/NCT05645094","created_at":"2022-12-09T14:57:45.690Z","updated_at":"2024-07-02T16:35:59.207Z","phase":"","brief_title":"Neoadjuvant Envafolimab in Resectable and Locally Advanced MSI-H/dMMR Rectal Cancer","source_id_and_acronym":"NCT05645094","lead_sponsor":"Fudan University","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enweida (envafolimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 01/01/2023","start_date":" 01/01/2023","primary_txt":" Primary completion: 06/01/2023","primary_completion_date":" 06/01/2023","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2022-12-13"},{"id":"4b3212dc-94b8-4477-92db-c1211e26a2ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT05534113","created_at":"2022-09-09T15:55:06.526Z","updated_at":"2024-07-02T16:36:03.944Z","phase":"Phase 2","brief_title":"Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC","source_id_and_acronym":"NCT05534113","lead_sponsor":"The First Affiliated Hospital with Nanjing Medical University","biomarkers":" EGFR • PD-L1","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • EGFR L858R • EGFR exon 19 deletion","tags":["EGFR • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • EGFR L858R • EGFR exon 19 deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ameile (aumolertinib) • Enweida (envafolimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 12/01/2022","start_date":" 12/01/2022","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2022-09-14"},{"id":"d68ed0d0-9939-4eec-84e3-ba9f80bab109","acronym":"","url":"https://clinicaltrials.gov/study/NCT05465733","created_at":"2022-07-20T13:55:12.880Z","updated_at":"2024-07-02T16:36:07.135Z","phase":"Phase 2","brief_title":"First-line Replacement Maintenance of Envafolimab in Advanced NSCLC","source_id_and_acronym":"NCT05465733","lead_sponsor":"First Affiliated Hospital Xi'an Jiaotong University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pemetrexed • Enweida (envafolimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2022-07-20"},{"id":"1f4197cf-21fb-47be-8241-dcef1e3927d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05417230","created_at":"2022-06-14T22:56:21.714Z","updated_at":"2024-07-02T16:36:08.935Z","phase":"Phase 2","brief_title":"RC48-ADC Combinatioed Envolizumab in Locally Advanced or Metastatic Biliary Tract Cancer With Positive HER-2","source_id_and_acronym":"NCT05417230","lead_sponsor":"Jiangsu Cancer Institute \u0026 Hospital","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Aidixi (disitamab vedotin) • Enweida (envafolimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 29","initiation":"Initiation: 08/01/2022","start_date":" 08/01/2022","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2022-06-14"},{"id":"021c374c-47e7-47a5-85c7-c84c4614867a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05371197","created_at":"2022-05-12T15:56:33.174Z","updated_at":"2024-07-02T16:36:10.541Z","phase":"Phase 2","brief_title":"Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer","source_id_and_acronym":"NCT05371197","lead_sponsor":"Third Affiliated Hospital, Sun Yat-Sen University","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enweida (envafolimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 05/05/2022","start_date":" 05/05/2022","primary_txt":" Primary completion: 06/30/2024","primary_completion_date":" 06/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2022-05-12"},{"id":"0e384b9e-72e4-4362-8332-971b95b05899","acronym":"NSCLC-LXL002","url":"https://clinicaltrials.gov/study/NCT05360979","created_at":"2022-05-05T00:56:32.433Z","updated_at":"2024-07-02T16:36:11.006Z","phase":"Phase 2","brief_title":"A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC","source_id_and_acronym":"NCT05360979 - NSCLC-LXL002","lead_sponsor":"Second Xiangya Hospital of Central South University","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enweida (envafolimab)"],"overall_status":"Enrolling by invitation","enrollment":" Enrollment 42","initiation":"Initiation: 05/15/2022","start_date":" 05/15/2022","primary_txt":" Primary completion: 05/15/2023","primary_completion_date":" 05/15/2023","study_txt":" Completion: 05/15/2025","study_completion_date":" 05/15/2025","last_update_posted":"2022-05-04"},{"id":"346abc56-e950-4714-8feb-b857e5924ad3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03101488","created_at":"2021-01-18T15:16:49.075Z","updated_at":"2024-07-02T16:36:16.105Z","phase":"Phase 1","brief_title":"Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT03101488","lead_sponsor":"3D Medicines (Sichuan) Co., Ltd.","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enweida (envafolimab)"],"overall_status":"Completed","enrollment":" Enrollment 287","initiation":"Initiation: 03/21/2017","start_date":" 03/21/2017","primary_txt":" Primary completion: 09/02/2019","primary_completion_date":" 09/02/2019","study_txt":" Completion: 08/25/2020","study_completion_date":" 08/25/2020","last_update_posted":"2022-03-03"},{"id":"f3c98868-0b75-43e3-9df8-fe89f66dc24d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05055167","created_at":"2021-09-24T14:55:05.406Z","updated_at":"2024-07-02T16:36:24.029Z","phase":"Phase 2","brief_title":"Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC","source_id_and_acronym":"NCT05055167","lead_sponsor":"The First Affiliated Hospital of Xiamen University","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enweida (envafolimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 08/30/2021","start_date":" 08/30/2021","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2021-09-24"}]